This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.

2. The term “Issuer” includes the Issuer and any of its subsidiaries.

3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap and continues to hold regular management meetings to discuss all aspects of the Company’s business plan. It executes action items that result from these meetings.

Management’s primary areas of focus continue to include:

• Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.

• These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America, which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.

• Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark’s metabolomics assay. Preliminary results from the retrospective, cancer-confirmed patient cohort, which includes an expanded non-cancer control group, have been analyzed, and the robust results met all assay performance metrics—high sensitivity and specificity. The company is discussing with key opinion leaders at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) on where and when to publish the data. Additional data on the prospective lung cancer screening cohort continues to be collected in 2026 as detailed in the clinical design. Pending the outcome of the results, the company intends to present it at a major cancer symposium.

• Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there’s only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource constrained.

• Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:

• • Optimizing our lab operations

  • Achieving clinical lab certification

  • Driving U.S. expansion

  • Fueling business development

  • Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment.

2. Provide a general overview and discussion of the activities of management.

• Despite persistent global economic challenges and ongoing geopolitical tensions, the company is strategically positioned to navigate these hurdles and capitalize on the significant opportunities within the oncology molecular diagnostics sector. Our core expertise in metabolomics and AI-driven biomarker discovery directly addresses the need for earlier, accessible, and more precise cancer detection. While navigating a cautious investment landscape and a competitive talent market, the Company has proactively implemented agile strategies and resilient operational and financial systems to counteract these headwinds. Furthermore, recognizing the transformative power of technology, the Company is strategically building a robust AI infrastructure through key collaborations, aiming to leverage advanced analytics to enrich assay results and enhance its cancer diagnostics capabilities. The company is committed to continuous innovation and disciplined execution to realize the full potential of these opportunities for our stakeholders.

• BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. The funding landscape shows recovery with continued selectivity for investment. This environment particularly challenges emerging diagnostic companies like BioMark, as investors continue to prioritize clinical-stage companies with proven concepts. Investor caution and a skilled labor shortage in bioinformatics are impacting the industry. Financing timelines are extended, making fundraising particularly challenging for small-cap diagnostic companies.

• On December 1^st, 2025, BioMark announced that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ Innovation Awards Gala. The award ceremony, held on November 27, 2025, celebrated the collaboration between Quebec-based BioMark Diagnostic Solutions, AstraZeneca Canada, Pfizer Canada and the IUCPQ-UL research team (Dr. Philippe Joubert and Dr. Yohan Bossé). The recognition highlights the successful development of an innovative multimodal approach designed to predict lung cancer risk, enabling simpler, earlier, and less invasive screening. At the heart of this initiative is BioMark’s metabolomic blood test, which combines the analysis of blood biomarkers with clinical data using artificial intelligence to calculate the probability of lung cancer presence. The award highlights the power of combining academic excellence with industrial innovation to bring life-saving diagnostic tools to market.

• BioMark Diagnostic Solutions, based in Quebec, together with Dr. Miller, submitted the full application for the ARENA Project funded by CQDM on December 4, 2025. The proposal focuses on BioMark’s lipid nanoparticle (LNP) platform and its selective gene knockdown program targeting glioblastoma (GBM), aligning with Quebec’s strategic priorities in advancing RNA-based therapeutic technologies. Any positive outcome will be subsequently disclosed.

About The ARENA program – Québec’s RNA Hub – is funded by the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE) and managed by CQDM, with a total budget of $3M. It supports Quebec-based biopharma companies in developing innovative RNA technologies from proof of concept to pre-commercialization. Eligible projects may involve improvements in RNA manufacturing, delivery technologies, biological property optimization, and new RNA-based therapeutic modalities. Selected projects may receive up to $300,000 over a period of up to 18 months.

• BioMark successfully held its Annual General Meeting on December 22, 2025, at 9:00 am (Vancouver Time) from its head office in Richmond, BC. All the motions were passed.

• On December 22, 2025, the manuscript titled “Translational Impact of Machine Learning-Driven Predictive Modeling with Pathway-Based Plasma Metabolomic Biomarkers for Lung Cancer Detection,” prepared by Dr. Maria Vaida’s team at Harrisburg University, Saint Boniface Research Centre, and BioMark was accepted for publication by Frontiers in Oncology, section Thoracic Oncology. In addition, several other papers are in the pipeline for later submissions to relevant journals.

• On December 23, 2025, BioMark announced that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025. This initiative marks a pivotal step in BioMark’s transition from research and development to a commercial-stage diagnostic company. The internationally recognized ISO 15189 certification serves as a fundamental accelerator for accessing global markets, providing a streamlined regulatory pathway and reducing potential commercial bottlenecks. Following the anticipated ISO 15189 accreditation, the Company intends to seek CLIA and CAP accreditations, which will enable BioMark to service the U.S. cancer diagnostic market with its Laboratory Developed Tests (LDTs).

• On December 30, 2025, BioMark announced that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company’s Annual General Meeting (AGM) held on December 22nd, 2025. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. The existing board and the BioMark management team are pleased to welcome Mr. Lavender and believe his expertise will provide important counsel and connectivity as the Company advances its commercialization roadmap and executes on its plan to enter the U.S. market.

• On December 31, 2025, BioMark issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux, BioMark: 2025 Achievements and 2026 Vision, celebrating a year of extraordinary achievement.

• Following BioMark’s October 7, 2025, announcement regarding its participation in the landmark HANSE lung cancer screening trial in Germany, significant progress has been achieved. By the end of December 2025, nearly 3000 samples have been successfully analyzed at BioMark’s laboratory in Quebec City. The HANSE trial continues to advance as planned, marking a key milestone in BioMark’s global clinical and market validation efforts. Regular meetings continue to be held with HANSE group tumor board members.

• The Company has been approached by multiple international institutions and investment brokers regarding potential partnerships and licensing opportunities aligned with its commercialization strategy. While discussions remain at a preliminary stage, any material developments will be disclosed in future updates. In addition, BioMark received interest from two U.S. states exploring potential business expansion opportunities. Any substantive progress in these discussions will be announced in subsequent monthly reports.

• BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks that are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2025.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 5^th, 2026